A retrospective, real-world study of tolerability of venetoclax-based therapy in combination with azole antifungal therapy for acute myeloid leukaemia in remission
Latest Information Update: 20 Jul 2020
Price :
$35 *
At a glance
- Drugs Posaconazole (Primary) ; Venetoclax (Primary) ; Azacitidine; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 20 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association